Botulinum Toxin Index

Botulinum Index connects product identities, company roles, regional approvals, scientific concepts, clinical-use context, and the people and organizations that have shaped the field. The emphasis is on relationships that are easy to blur: developer versus manufacturer, owner versus commercialization partner, global brand name versus local label, and clinical discussion versus an approved indication.

Explore the Index

Area	What it connects	Start here
Companies	Developers, manufacturers, owners, approval holders, and commercialization partners	Company directory
Brands and products	Product identity, toxin type, formulation context, regional names, and company relationships	Brand directory
Regulatory reference	Historical U.S. approval anchors and current product-specific labeled indications	FDA approval timeline and FDA indication matrix
Science	Toxin biology, serotypes, mechanism, diffusion, immunogenicity, and comparison limits	Botulinum toxin
Clinical context	Conditions, treatment goals, label boundaries, units, handling, anatomy, and safety interpretation	Clinical uses and clinical practice
Industry network	Scientists, physicians, executives, societies, congresses, and market-facing events	People and organizations and events

Key Reference Datasets

Reference	Question it helps answer	Scope
Brand-to-company map	Who developed, manufactures, owns, or commercializes a product?	Major represented product families and the distinct roles of related companies
U.S. brand map	Which major aesthetic type A brands are visible in the United States?	Product identity, approval anchors, and company context without unit equivalence
U.S. FDA indication matrix	Which current U.S. labels include a particular indication or patient population?	Product-specific labeled uses; not a universal clinical-use table
U.S. FDA approval timeline	When did major U.S. regulatory milestones occur?	Historical approval anchors separated from current label evidence
Type A vs type B	How do serotypes, products, units, and clinical roles differ?	Biological and regulatory comparison without implying substitutability

How Products Connect

Product or family	Connected companies	Relationship
Botox / Botox Cosmetic	AbbVie / Allergan	Allergan built the franchise; AbbVie is the current parent-company context.
Dysport	Ipsen and Galderma	Ipsen is tied to product origin and the therapeutic business, while Galderma commercializes aesthetic Dysport-family products in licensed territories.
Jeuveau / Nabota	Daewoong Pharmaceutical and Evolus	Daewoong manufactures the product; Evolus commercializes Jeuveau in the United States and Nuceiva in selected international markets.
Daxxify	Revance / Crown Laboratories	Revance developed Daxxify; Crown Laboratories is the current parent-company context.
Letybo / Botulax	Hugel	One Korea-origin product family appears under different names and regulatory contexts across markets.

These relationships describe industry structure, not clinical rank. A shared company, toxin type, or product-family history does not establish identical labels, formulations, indications, units, safety profiles, or clinical performance.

Interpretation boundaries

• Approvals and labels are specific to a product and jurisdiction.
• Potency units are product-specific and cannot be assumed to be interchangeable.
• A familiar brand name or common clinical use does not prove approval in a particular market.
• Ownership, licensing, and settlement history do not establish clinical superiority.

Sources and Status

Medical, regulatory, formulation, approval, and product-specific claims are linked where appropriate to prescribing information, regulator records, peer-reviewed literature, and official company disclosures. Changing information such as approvals, ownership, leadership, and market availability should be read with the stated market, source date, and status context attached.

Share Your Industry Expertise

Botulinum Index also publishes perspectives from professionals working across the botulinum toxin industry. Contributions may cover research, manufacturing, clinical practice, regulation, education, commercialization, regional markets, or direct experience with a company, product, or technology.

Published articles include clear authorship and professional context, and selected contributions are translated across all nine language editions. They can also be connected with relevant companies, brands, people, markets, and reference topics throughout the index. See the contribution guidelines and submit an article.